Compound library / Muscle Growth
Soluble decoy receptor fusion protein targeting the ActRIIB pathway, blocking myostatin and related ligands to promote muscle growth. Explored for Duchenne muscular dystrophy and healthy muscle gain in preclinical and early clinical work.
| Category | Muscle Growth |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~14 days (Fc fusion extends half-life significantly) |
| Common dose range | Research-stage; clinical trial doses were 1-3 mg/kg |
| Typical cycle length | Not well established for general use |
BioHack Track models ACE-031 (ACVR2B-Fc) at a half-life of 336 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Reconstitute with bacteriostatic water per supplier guidance.
Refrigerate after reconstitution.
Caused epistaxis and telangiectasias in early clinical trials, leading to pause in development. Potent — grey-market use carries significant unknown risk.
Track ACE-031 (ACVR2B-Fc) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for ACE-031 (ACVR2B-Fc) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.